The aim of this study was to determine the species of microorganisms isolated from patients in intensive care units (ICU) of our hospital and to assess the in-vitro efficacy of various antimicrobial agents on these organisms. Growth of bacteria and Candida were observed in 209 (91.67%) and 19 (8.33%) out of 675 clinical samples between 01.Jan.2003-31.Mar.2003 , respectively. Sixty three (29.65%) of the bacterial isolates were from tracheal aspirates, 59 (28.22%) from blood, 38 (18.18%) from urine, 30 (14.34%) from sterile body fluids, 17 (8.13%) from wound and 2 (0.95%) from cathater cultures. VITEC and API 20E, API 20NE, API STAPH and API STREP (bioMerieux, France) were used for identification of bacteria. The most frequently isolated microorganisms were S.aureus (19.61%), S.epidermidis (17.22%), P.aeruginosa (17.22%), A.calcoaceticus (13.87%) and K.pneumoniae (9.56%). Antimicrobial resistance pattern of these microorganisms were tested by using VITEC GPS 101, GNS 111 and GNS 528 (bioMerieux, France). 15 (78.90%) Candida strains were isolated from urine, 2 (10.52%) from tracheal aspirates, 1 (5.26) from sterile body fluids and 1 (5.26%) from wound cultures. From the clinical samples, 11 (57.89%) C.albicans 3 (15.78%) C.tropicalis, 2 (10.52%) C.glabrata , 1 (5.26%) C.utilis, 1 (5.26%) C.sake, 1 (5.26%) C.norvagensis were identified. API ID 32C (bioMerieux, France) was used for the identification of Candida strains . The in-vitro antifungal susceptibility testing was performed by using ATB FUNGUS (bioMerieux, France) and all of the strains were found to be as susceptible to all antifungals used.